Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414076 | 0.82 | PIN1 (0.51) | ALDH1A1MAPTRAB9ANPSR1SMN1; SMN2 | |
| SCHEMBL6567167 | 0.81 | MAPT (0.49) | L3MBTL1ALDH1A1POLBMAPTNPSR1 | |
| SCHEMBL1201480 | 0.79 | KDR (0.43) | POLBMAPTRAB9ANPSR1TDP1 | |
| SCHEMBL3506280 | 0.79 | MAPT (0.70) | L3MBTL1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL4607970 | 0.79 | MAPT (0.47) | ALDH1A1POLBMAPTNPSR1TDP1 | |
| SCHEMBL7781854 | 0.77 | MAPT (0.54) | L3MBTL1ALDH1A1POLBMAPTNPSR1 | |
| SCHEMBL31176892 | 0.77 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1POLBMAPTMAPK1 | |
| SCHEMBL22529894 | 0.75 | PIN1 (0.55) | ALDH1A1POLBMAPTRAB9AGAA | |
| SCHEMBL29349900 | 0.75 | PIN1 (0.55) | ALDH1A1POLBMAPTRAB9AGAA | |
| SCHEMBL8917615 | 0.75 | MAPT (0.37) | ALDH1A1POLBMAPTRAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
| EP-1841766-A1 | PYRROLOPYRIDINES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077401-A1 | PYRROLOPYRIDINES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | L3MBTL1 3595/4885ALDH1A1 2562/4885POLB 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.